Validation to velocity: Japan’s pharma model comes under execution pressure - Pharmaceutical Technology

Japan’s pharmaceutical sector is gradually reorienting from deep, validation-led development towards execution-driven partnerships, as global pressure compresses timelines across drug development. Japan’s pharmaceutical sector is gradually reorienting from deep, validation-led development towards execution-driven partnerships, as global pressure compresses timelines across drug development. Japan’s pharmaceutical market is the third largest in the world, following the United States and China. Credit: Vitalii Stock via Shutterstock.com. Japan’s pharmaceutical industry – the world’s third largest by market value after the United States and China – has long been associated with methodical development cycles and rigorous technical validation. But the sector is undergoing a gradual…

Source: Pharmaceutical Technology